Table 2.
Stoichiometry.
| Study (year) | Cell line | Enrichment method | Quantitation | Stoichiometry estimation | Identified sites | Ref. |
|---|---|---|---|---|---|---|
| Olsen et al. (2010) | HeLa (cell cycle progression) | SCX/TiO2 | SILAC | Data-dependent stoichiometry estimation | 20,443 phosphorylation sites, 6027 proteins | [22] |
| Wu et al. (2011) | Yeast | HILIC | Chemical labeling with stable isotopes | Phosphatase treatment | 5033 phosphorylation sites | [79] |
| Sharma et al. (2014) | HeLa (Cell cycle progression and EGF stimulation) | SCX/TiO2 | Label-free | Data-dependent stoichiometry estimation | 50,000 phosphorylation sites | [23] |
| Tsai et al. (2015) | Gefitinib-sensitive and resistant human lung adenocarcinoma cell line PC9, Raji human B cell line | IMAC purification (Followed by kinase reaction) | Isotopic tagging with dimethyl labeling | Phosphatase treatment in combination with kinase assay | 1000 phosphorylation sites | [80] |
Phosphoproteomics analyses including stoichiometry measurements: Biological context of the experiments, Phosphopeptide enrichment method, quantitation method, stoichiometry measurement method, number of identified sites and reference.
SCX: Strong cation exchange; TiO2: Titanium dioxide